Additional Lignan Research: Breast Health

Cancer Res Treat. 2003 May;79(1):17-23. Enterolactone in breast cyst fluid: correlation with EGF and breast cancer risk. Boccardo F, Lunardi GL, Petti AR, Rubagotti A.Professorial Unit of Medical Oncology, University and National Cancer Research Institute, Genoa, Italy.
email: francesco.boccardo@istge.it.

Exp Biol Med (Maywood). 2004 May;229(5):417-24. Chemopreventive effects of hydroxymatairesinol on uterine carcinogenesis in Donryu rats. Katsuda S, Yoshida M, Saarinen N, Smeds A, Nakae D, Santti R, Maekawa A. Department of Biological Safety Research, Japan Food Research Laboratories, Tama-shi, Tokyo 206-0025, Japan.
email:katudas@jfrl.or.jp.

Eur J Cancer Prev. 2002 Aug;11 Suppl 2:S48-57. Antioxidant and antitumor effects of hydroxymatairesinol (HM-3000, HMR), a lignan isolated from the knots of spruce. Kangas L, Saarinen N, Mutanen M, Ahotupa M, Hirsinummi R, Unkila M, Perala M, Soininen P, Laatikainen R, Korte H, Santti R. Hormos Nutraceutical Ltd, Turku, Finland.

Mol Cancer Ther. 2002 Aug;1(10):869-76. Enterolactone inhibits the growth of 7,12-dimethylbenz(a)anthracene-induced mammary carcinomas in the rat. Saarinen NM, Huovinen R, Warri A, Makela SI, Valentin-Blasini L, Sjoholm R, Ammala J, Lehtila R, Eckerman C, Collan YU, Santti RS. Institute of Biomedicine, Department of Anatomy, University of Turku, FIN-20520 Turku, Finland.